For the quarter ending 2026-03-31, EIKN had $56,290K increase in cash & cash equivalents over the period. -$90,063K in free cash flow.
| Cash Flow | 2026-03-31 |
|---|---|
| Net loss | -82,958 |
| Depreciation expense | 5,214 |
| Stock-based compensation expense | 2,777 |
| Amortization of operating lease right-of-use assets | 101 |
| Amortization of premiums and accretion of discounts on marketable securities | 827 |
| Prepaid expenses and other current assets | 4,377 |
| Other assets | -2,700 |
| Accounts payable | 5,324 |
| Accrued expenses and other current liabilities | -15,065 |
| Operating lease liabilities | -2,488 |
| Net cash used in operating activities | -89,801 |
| Purchase of property and equipment | 262 |
| Purchase of marketable securities | 306,955 |
| Proceeds from maturities of marketable securities | 104,000 |
| Net cash used in investing activities | -203,217 |
| Proceeds from issuance of common stock under stock plans | 277 |
| Proceeds from initial public offering, net of issuance costs | 349,031 |
| Net cash provided by financing activities | 349,308 |
| Net increase in cash, cash equivalents and restricted cash | 56,290 |
| Cash, cash equivalents and restricted cash at beginning of period | 113,072 |
| Cash, cash equivalents and restricted cash at end of period | 169,362 |
Eikon Therapeutics, Inc. (EIKN)
Eikon Therapeutics, Inc. (EIKN)